This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
immunoglobulin-g
Immunoglobulin G
Y-shaped tetrameric antibody (2 heavy + 2 light chains) — the most abundant serum immunoglobulin (~10–15 mg/mL), with ~21-day half-life. Four subclasses (IgG1–4). Principal mediator of humoral immunity and vaccine-elicited protection.
Entry Metadata
| Field | Value |
|---|---|
| ID | immunoglobulin-g |
| Name | Immunoglobulin G |
| Status | draft |
| Last reviewed | 2026-06-04 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
expressed-byPlasma Cell
targetsSars Cov 2
targetsInfluenza A
part-ofImmune System
targetsHiv 1
targetsHepatitis B Virus
targetsStreptococcus Pneumoniae
connects-toMyasthenia Gravis
connects-toFcrn
connects-toImmune Thrombocytopenia
connects-toCidp
connects-toDermatomyositis
connects-toAnca Vasculitis
connects-toDesmoglein 3
connects-toPemphigus Vulgaris
connects-toBeta2 Glycoprotein 1
connects-toAntiphospholipid Syndrome
connects-toAdamts13
connects-toThrombotic Thrombocytopenic Purpura
connects-toHemophilia A
connects-toPlacenta
Sources
- Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 9th ed. Elsevier; 2018.
- Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41-52. · PubMed 20176268
- Ward ES, Bhatt DL, Bhatt DL, et al. The role of FcRn in immunity and its therapeutic implications. Nat Rev Immunol. 2020;20(7):399-407. · PubMed 32015434
- Subbarao K. The success of SARS-CoV-2 vaccines and prospects for the future. Nat Rev Immunol. 2021;21(8):469-470. · PubMed 34155386
- World Health Organization. The WHO International Standard for anti-SARS-CoV-2 immunoglobulin. WHO/BS/2020.2403.